Ajmer Singh Grewal, Neelam Sharma, Sukhbir Singh and Sandeep Arora, Chitkara College of Pharmacy, Chitkara University, Rajpura, Patiala, 140401, Punjab, India
Alpha-glucosidase, Dipeptidyl peptidase 4, Glucagon receptor, Glucokinase, Glycogen synthase kinase 3, Phenolic compounds, Syzygium cumini
Treatment of type 2 diabetes without any side effects is still a challenge to the medical system. This leads to increasing demand for natural products with antidiabetic activity with fewer side effects. Syzygium cumini is a traditional herbal medicinal plant and is reported to possess a variety of pharmacological actions. It contains various types of chemical constituents including terpenoids, tannins, anthocyanins, flavonoids and other phenolic compounds. Some flavonoids and other phenolic compounds from S. cumini were reported in literature to have type 2 antidiabetic potential. The main objective of the current investigation was in silico screening of some phenolic compounds from S. cumini against multiple targets associated with type 2 diabetes to explore the mechanism of antidiabetic action and prediction of binding mode using molecular docking studies.
Afify, A. M. R., Fayed, F. A., Shalaby, E. A. and El-Shemy, H. A. (2011). Syzygium cumini (pomposia) active principles exhibit potent anticancer and antioxidant activities. African Journal of Pharmacy and Pharmacology, 5(7), 948–956.
Avila-Pena, D., Pena, N., Quintero, S. L. and Suarez-Roca, H. (2007). Antinociceptive activity of Syzygium jambos leaves extract on rats. Journal of Ethnopharmacology, 112(2), 380–385. https://doi.org/10.1016/j.jep.2007.03.027
Ayyanar, M. and Subash-Babu, P. (2012). Syzygium cumini (L.) Skeels: a review of its phytochemical constituents and traditional uses. Asian Pacific Journal of Tropical Biomedicine, 2, 240–246. https://doi.org/10.1016/S2221-1691(12)60050-1
Bardy, G., Virsolvy, A., Quignard, J., Ravier, M., Bertrand, G., Dalle, S., et al. (2013). Quercetin induces insulin secretion by direct activation of L-type calcium channels in pancreatic beta cells. British Journal of Pharmacology, 169, 1102–1113. https://doi.org/10.1111/bph.12194
Bastaki, S. (2005). Diabetes mellitus and its treatment. International Journal of Diabetes Metabolism, 13, 111–134.
Bijauliya, R. K., Alok, S., Singh, M. and Mishra, S. B. (2017). Morphology, phytochemistry and pharmacology of Syzygium cumini (Linn.) – an overview. International Journal of Pharmaceutical Sciences and Research, 8(6), 2360–2371.
Brito, F. A., Lima, L. A., Ramos, M. F., Nakamura, M. J., Cavalher-Machados, S. C., Henrigues, M. G., et al. (2007). Pharmacological study of anti-allergic activity of Syzygium cumini (L) Skeels. Brazillian Journal of Medical and Biological Research, 40, 105–115. https://doi.org/10.1590/S0100-879X2007000100014
Cade, W. T. (2008). Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Physical Therapy, 88, 1322–1335. https://doi.org/10.2522/ptj.20080008
Chagas, V. T., França, L. M., Malik, S. and Paes, A. M. A. (2015). Syzygium cumini (L.) skeels: a prominent source of bioactive molecules against cardiometabolic diseases. Frontiers in Pharmacology, 6, Article 259. https://doi.org/10.3389/fphar.2015.00259
Charaya, N., Pandita, D., Grewal, A. S. and Lather, V. (2018). Design, synthesis and biological evaluation of novel thiazol-2-yl benzamide derivatives as glucokinase activators. Computational Biology and Chemistry, 73, 221–229. https://doi.org/10.1016/j.compbiolchem.2018.02.018